
    
      Primary Objective is to provide access to therapy with 131I-MIBG for patients with
      relapsed/refractory neuroblastoma or metastatic pheochromocytoma.

      Secondary Objectives are to (1) assess disease response to 131I-MIBG therapy for patients
      with relapsed/refractory neuroblastoma or metastatic pheochromocytoma; (2) gain more
      information about the toxicities of 131I-MIBG therapy; and (3) assess improvement of
      symptoms, including pain and fatigue, for patients with relapsed/refractory neuroblastoma or
      metastatic pheochromocytoma who are receiving 131I-MIBG therapy.
    
  